Catalyst Funds Management Pty LTD Protalix Bio Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $409 Billion
- Q4 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 10,200 shares of PLX stock, worth $25,398. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,200
Previous 10,200
-0.0%
Holding current value
$25,398
Previous $10.4 Million
84.31%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
4.58MCall Options Held
40.9KPut Options Held
5.3K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.12MShares$2.78 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL732KShares$1.82 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny388KShares$965,9230.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$829,5950.0% of portfolio
-
Gsa Capital Partners LLP London, X0306KShares$761,3150.04% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $124M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...